The United States Food and Drug Administration (FDA) has approved three drugs for non-prescription, or over-the-counter use via a process called a prescription (Rx)-to-OTC switch, it was reported on Friday.
The FDA approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1%) intended for the temporary relief of arthritis pain; Pataday Twice Daily Relief (olopatadine HCl ophthalmic solution/drops, 0.1%) intended for the temporary relief of itchy and red eyes due to pollen, ragweed, grass, animal hair or dander; and Pataday Once Daily Relief (olopatadine HCl ophthalmic solution/drops, 0.2%) for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander, for non-prescription use.
The FDA granted the approval of non-prescription Voltaren Arthritis Pain to GlaxoSmithKline plc. Approvals of non-prescription Pataday Twice Daily Relief and Pataday Once Daily Relief was granted to Alcon.
The three products will be marketed in the United States as non-prescription drugs and will no longer be offered as prescription drugs.
Egetis receives US notice of allowance for MCT8 deficiency composition patent
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117